Myriad Genetics is Exclusive Licensee of New Mayo Clinic Patent on Amyloid Lowering Drugs

01-Jul-2005

Myriad Genetics, Inc. announced the issuance of Patent No. 6,911,466 entitled, "Ab42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic Peptide.

Amyloid beta 42 is a neurotoxic peptide that is the primary constituent of senile plaques that accumulate in the brains of patients with Alzheimer's disease. It is thought to be the key initiator of Alzheimer's disease since this peptide has the greatest tendency to aggregate, cause neuronal damage and initiate amyloid deposits in the brain. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances